Skip to main content


Latest articles

19-04-2021 | Oncology | News | Article

FDA approves sacituzumab govitecan for advanced urothelial cancer

Find out more details about this accelerated approval here

19-04-2021 | Oncology | News | Article

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC

Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.

16-04-2021 | Oncology | News | Article

ESMO issues recommendations for SCLC management

More information on these Clinical Practice Guidelines available here

16-04-2021 | Oncology | News | Article

Outliers in link between obesity and poor cancer survival reinforced in meta-analysis

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

15-04-2021 | Oncology | News | Article

Sintilimab could be a viable second-line option for advanced squamous NSCLC

Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.

15-04-2021 | Oncology | News | Article

Tislelizumab offers improved outcomes over docetaxel in advanced NSCLC

The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.

Image Credits